The content on this site is intended for healthcare professionals only
Dr Bernd Kasper presents his study, at ESMO 2022, of the DeFi trial a phase 3, randomised controlled trial of nirogacestat versus placebo for progressing desmoid tumours (DT).
DT are rare, locally aggressive soft-tissue tumours without approved systemic therapy. Nirogacestat, a novel oral gamma secretase inhibitor has shown antitumour activity in patients with DT.
Nirogacestat demonstrated statistically and clinically significant improvements in PFS, ORR, symptom burden, physical/role functioning, and health-related quality of life and had a manageable safety profile in adults with progressing DT.
Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated advanced lung cancer
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Olaparib plus ceralasertib might benefit paediatric cancer patients with DNA repair-deficient tumours
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
